Late toxicity after intensity-modulated radiation therapy for localized prostate cancer: an exploration of dose-volume histogram parameters to limit genitourinary and gastrointestinal toxicity.

[1]  M. Parmar,et al.  Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: first results from the MRC RT01 randomised controlled trial. , 2007, The Lancet. Oncology.

[2]  K. Choe,et al.  External beam radiotherapy for prostate cancer patients on anticoagulation therapy: how significant is the bleeding toxicity? , 2010, International journal of radiation oncology, biology, physics.

[3]  A. Hanlon,et al.  Late morbidity profiles in prostate cancer patients treated to 79-84 Gy by a simple four-field coplanar beam arrangement. , 2003, International journal of radiation oncology, biology, physics.

[4]  G. Ezzell,et al.  Analysis of biochemical control and prognostic factors in patients treated with either low-dose three-dimensional conformal radiation therapy or high-dose intensity-modulated radiotherapy for localized prostate cancer. , 2007, International journal of radiation oncology, biology, physics.

[5]  H. von der Maase,et al.  Dose-volume histograms associated to long-term colorectal functions in patients receiving pelvic radiotherapy. , 2005, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[6]  Alexandra L Hanlon,et al.  Prostate cancer radiotherapy dose response: an update of the fox chase experience. , 2004, The Journal of urology.

[7]  Michael J Chen,et al.  Intensity modulated radiotherapy for localized prostate cancer: rigid compliance to dose-volume constraints as a warranty of acceptable toxicity? , 2007, Radiation oncology.

[8]  A. D'Amico,et al.  NCCN clinical practice guidelines in oncology: prostate cancer. , 2010, Journal of the National Comprehensive Cancer Network : JNCCN.

[9]  Yoshiya Yamada,et al.  Long-term outcome of high dose intensity modulated radiation therapy for patients with clinically localized prostate cancer. , 2006, The Journal of urology.

[10]  K. Zorn,et al.  External beam radiation therapy after transurethral resection of the prostate: a report on acute and late genitourinary toxicity. , 2010, International journal of radiation oncology, biology, physics.

[11]  I. Hsu,et al.  Proposed rectal dose constraints for patients undergoing definitive whole pelvic radiotherapy for clinically localized prostate cancer. , 2008, International journal of radiation oncology, biology, physics.

[12]  Anthony D'Amico,et al.  Prostate cancer. Clinical practice guidelines in oncology. , 2007, Journal of the National Comprehensive Cancer Network : JNCCN.

[13]  C. Pelizzari,et al.  Biochemical Control and Toxicity after Intensity-Modulated Radiation Therapy for Prostate Cancer , 2009, Technology in cancer research & treatment.

[14]  Riccardo Calandrino,et al.  Significant correlation between rectal DVH and late bleeding in patients treated after radical prostatectomy with conformal or conventional radiotherapy (66.6-70.2 Gy). , 2002, International journal of radiation oncology, biology, physics.

[15]  Vitali Moiseenko,et al.  Effect of bladder filling on doses to prostate and organs at risk: a treatment planning study , 2007, Journal of applied clinical medical physics.

[16]  K. M. Ayyangar,et al.  Dose volume histogram comparison between ADAC Pinnacle and Nomos Corvus systems for IMRT , 2009, Australasian Physics & Engineering Sciences in Medicine.

[17]  George Starkschall,et al.  Late rectal toxicity: dose-volume effects of conformal radiotherapy for prostate cancer. , 2002, International journal of radiation oncology, biology, physics.

[18]  P. Koper,et al.  Localized volume effects for late rectal and anal toxicity after radiotherapy for prostate cancer. , 2005, International journal of radiation oncology, biology, physics.

[19]  W. De Neve,et al.  Intensity-modulated radiation therapy for prostate cancer: late morbidity and results on biochemical control. , 2007, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[20]  Lei Dong,et al.  Investigation of bladder dose and volume factors influencing late urinary toxicity after external beam radiotherapy for prostate cancer. , 2007, International journal of radiation oncology, biology, physics.

[21]  Steve Webb,et al.  Dose-volume constraints to reduce rectal side effects from prostate radiotherapy: evidence from MRC RT01 Trial ISRCTN 47772397. , 2010, International journal of radiation oncology, biology, physics.

[22]  G. Sanguineti,et al.  Dose-volume effects for normal tissues in external radiotherapy: pelvis. , 2009, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[23]  K. Forster,et al.  Treatment planning system evaluation for mesothelioma IMRT. , 2005, Lung cancer.

[24]  Ping Xia,et al.  Can all centers plan intensity-modulated radiotherapy (IMRT) effectively? An external audit of dosimetric comparisons between three-dimensional conformal radiotherapy and IMRT for adjuvant chemoradiation for gastric cancer. , 2008, International journal of radiation oncology, biology, physics.

[25]  George Starkschall,et al.  Prostate cancer radiation dose response: results of the M.D. Anderson phase III randomized trial , 2003 .

[26]  C. Lawton.  Long-term toxicity following 3D conformal radiation therapy for prostate cancer from the RTOG 9406 phase I/II dose escalation study , 2011 .

[27]  L. Gras,et al.  Estimation of the incidence of late bladder and rectum complications after high-dose (70-78 GY) conformal radiotherapy for prostate cancer, using dose-volume histograms. , 1998, International journal of radiation oncology, biology, physics.

[28]  J. Deasy,et al.  Radiation dose-volume effects in radiation-induced rectal injury. , 2010, International journal of radiation oncology, biology, physics.

[29]  G. Gustafson,et al.  Predictors for chronic urinary toxicity after the treatment of prostate cancer with adaptive three-dimensional conformal radiotherapy: dose-volume analysis of a phase II dose-escalation study. , 2007, International journal of radiation oncology, biology, physics.

[30]  W. Curran,et al.  Common toxicity criteria: version 2.0. an improved reference for grading the acute effects of cancer treatment: impact on radiotherapy. , 2000, International journal of radiation oncology, biology, physics.

[31]  B. Davis,et al.  Estimated limits of IMRT dose escalation using varied planning target volume margins , 2008, Physics in medicine and biology.

[32]  Daniel W. Miller,et al.  Comparison of conventional-dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: a randomized controlled trial. , 2005, JAMA.

[33]  Yoshiya Yamada,et al.  Ultra-high dose (86.4 Gy) IMRT for localized prostate cancer: toxicity and biochemical outcomes. , 2008, International journal of radiation oncology, biology, physics.

[34]  Alexandre Mamedov,et al.  Clinical results of long-term follow-up of a large, active surveillance cohort with localized prostate cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[35]  Joos V Lebesque,et al.  Dose-response in radiotherapy for localized prostate cancer: results of the Dutch multicenter randomized phase III trial comparing 68 Gy of radiotherapy with 78 Gy. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[36]  A B Jani,et al.  Comparison of late gastrointestinal and genitourinary toxicity of prostate cancer patients undergoing intensity-modulated versus conventional radiotherapy using localized fields , 2007, Prostate Cancer and Prostatic Diseases.

[37]  C. Fiorino,et al.  Clinical and dosimetric predictors of late rectal syndrome after 3D-CRT for localized prostate cancer: preliminary results of a multicenter prospective study. , 2008, International journal of radiation oncology, biology, physics.

[38]  J. Vaarkamp,et al.  A comparison of conformal and intensity modulated treatment planning techniques for early prostate cancer , 2009, Journal of medical imaging and radiation oncology.

[39]  Lei Dong,et al.  Long-term results of the M. D. Anderson randomized dose-escalation trial for prostate cancer. , 2008, International journal of radiation oncology, biology, physics.